文献速递乳腺乳腺X线MR

对比增强乳腺X线与MRI评估乳腺癌新辅助治疗肿瘤反应的直接比较:一项前瞻性多阅片者研究

Head‑to‑head comparison of contrast‑enhanced mammography and MRI in assessing the tumor response to neoadjuvant therapy in breast cancer: a prospective, multireader study.
PubMed 文献 · Radiol Med · 2025-08-12

本研究前瞻性纳入57例接受新辅助治疗的乳腺癌患者,比较对比增强乳腺X线与MRI评估肿瘤反应。CEM与MRI预测病理完全缓解的敏感度、特异度及准确率均无统计学显著差异,CEM敏感度略高、特异度略低;两种方法均轻度高估残留病灶范围,与病理一致性均较差。

要点

  • CEM预测pCR的敏感度0.778、特异度0.714、准确率0.754;MRI对应为0.714、0.944、0.860。
  • CEM与MRI均轻度高估残留病灶范围,平均高估分别为1.7 mm和2.7 mm。
  • CEM与MRI残留范围与病理一致性均较差,平均ICC分别为0.4467和0.449。

核心结论

  • 与MRI相比,CEM预测pCR的准确率相当但略低、敏感度较高、特异度较低;评估残留肿瘤范围时两者表现相似且均倾向于高估病理范围;CEM可能成为部分接受新辅助治疗患者的可接受替代选择。

研究设计与样本

  • 前瞻性多阅片者研究,纳入57例(年龄47±10岁)在新辅助治疗前后均接受CEM和乳腺MRI的患者,3名不同经验水平的阅片者独立评估图像并按新辅助治疗后肿瘤反应分类。

关键影像表现/征象

  • 影像学完全缓解定义为未见可疑强化区域。
  • 21/57例(36.8%)达到病理完全缓解。
  • CEM与MRI均轻度高估残留病灶范围,平均高估分别为1.7 mm和2.7 mm。

诊断标准与关键数值

  • CEM预测pCR的敏感度0.778、特异度0.714、准确率0.754(阅片者平均值)。
  • MRI预测pCR的敏感度0.714、特异度0.944、准确率0.860(阅片者平均值)。
  • CEM与MRI上述诊断效能比较的所有P值均>0.050。
  • CEM与病理残留范围一致性的平均ICC为0.4467,MRI为0.449,均提示一致性差。

临床应用与阅片要点

  • 阅片时以未见可疑强化区域作为影像学完全缓解的判断依据。
  • CEM预测pCR特异度低于MRI(0.714 vs 0.944),判读完全缓解需结合临床。
  • CEM与MRI评估残留范围均倾向高估病理范围(平均1.7 mm与2.7 mm)。
  • 作者认为CEM可能成为部分接受新辅助治疗患者中MRI的可接受替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare contrast-enhanced mammography (CEM) and MRI in the evaluation of the tumor response to neoadjuvant therapy (NAT) in breast cancer.

MATERIALS AND METHODS: Patients who underwent CEM and breast MRI before and after NAT were prospectively enrolled in this study. Three readers with different levels of experience independently assessed the images and classified the tumor response following NAT. Radiological complete response (rCR) was defined as the absence of a suspiciously enhanced area. The sensitivity, specificity, and accuracy of CEM and MRI in determining pathological complete response (pCR) were calculated per reader and averaged with a generalized estimating equation. The agreement in the residual tumor extent between imaging and pathology was assessed by intraclass correlation coefficient (ICC) analyses.

RESULTS: Fifty-seven patients (age: 47 ± 10 years) were enrolled, 21/57 of whom (36.8%) achieved pCR. In determining pCR, the estimated average sensitivity, specificity, and accuracy were 0.778, 0.714, and 0.754 for CEM, respectively, and 0.714, 0.944, and 0.860 for MRI, respectively (all P values > 0.050). Both imaging modalities slightly overestimated the residual lesion extent (mean overestimations: 1.7 mm and 2.7 mm). In ICC analysis, CEM and MRI showed poor consistency with pathology (average ICCs = 0.4467 and 0.449, respectively).

CONCLUSIONS: Compared with MRI, CEM showed comparable but slightly lower accuracy, higher sensitivity, and lower specificity in predicting pCR after NAT. In assessing residual tumor extent, CEM and MRI showed similar performance and tended to overestimate the pathological extent. CEM could be an acceptable alternative to MRI in certain patients undergoing NAT.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Wang S, Li J, Chen R, et al. Head‑to‑head comparison of contrast‑enhanced mammography and MRI in assessing the tumor response to neoadjuvant therapy in breast cancer: a prospective, multireader study. Radiol Med. 2025. PMID: 40794243. doi:10.1007/s11547-025-02068-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。